Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

Inclusion Criteria: * At least 1 of the following: 1. Untreated male with urethral gonorrhea as determined by a screening laboratory test (either NAAT or culture) for N. gonorrhoeae within 2 weeks prior to study drug administration. 2. Untreated female with cervical gonorrhea as determined by a screening laboratory test (either NAAT or culture) for N. gonorrhoeae within 2 weeks prior to study drug administration. 3. Urethral (male) or cervical (female) Gram stain demonstrating Gram-negative intracellular diplococci and leukocytes. * The patient must be willing to abstain from anal, oral, and vaginal sexual intercourse or use condoms for all of these until study completion. * Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrollment. Exclusion Criteria: * Confirmed or suspected complicated or systemic gonococcal infections such as pelvic inflammatory disease, epididymitis, arthritis, endocarditis, or disseminated gonococcal infection. * Individuals who have already received antibiotic treatment for their gonorrhea. * Use of systemic or intravaginal antibiotics within 7 days prior to study drug administration. * Women who are pregnant or nursing. * Men with suspected or confirmed rectal gonorrhea and symptoms of proctitis. * History of significant intolerance or allergy to macrolide or cephalosporin antibiotics.